Literature DB >> 7746417

Occupational outcome after temporal lobectomy for refractory epilepsy.

M R Sperling1, A J Saykin, F D Roberts, J A French, M J O'Connor.   

Abstract

We evaluated employment after temporal lobectomy for refractory epilepsy in 86 patients (3.5 to 8 years of follow-up). Seventy-three patients qualified for the work force before and after surgery. Unemployment rates declined after surgery (18 patients [25%] unemployed before surgery, eight patients [11%] unemployed after surgery), and underemployment also tended to diminish. Improvement in occupational status related strongly to the degree of postoperative seizure relief. Seizure-free patients fared better (no unemployment, little underemployment) than patients with some seizure-free years and some years with seizures after surgery, whose high underemployment level persisted. Patients with seizures in each year after surgery fared worst (despite reduced seizure frequency), with increased unemployment after surgery. Age at surgery also influenced vocational outcome in patients who were unemployed before surgery. Historical, educational, cognitive, and behavioral measures did not correlate with vocational outcome. Employment gains came slowly; unemployed patients took up to 6 years to obtain work after surgery. Of 13 students at the time of surgery, 11 have graduated and nine are now employed. We conclude that seizures play a large role in limiting employment, and that by alleviating seizures, temporal lobectomy improves employability in people with refractory epilepsy. Surgery thereby provides benefit to individuals with epilepsy by increasing financial independence and to society by reducing unemployment.

Entities:  

Mesh:

Year:  1995        PMID: 7746417     DOI: 10.1212/wnl.45.5.970

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Quality of life after epilepsy surgery.

Authors:  M W Kellett; D F Smith; G A Baker; D W Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  Long-term seizure and psychosocial outcomes of epilepsy surgery.

Authors:  José F Téllez-Zenteno; Samuel Wiebe
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

Review 3.  Anterior temporal lobectomy, hippocampal sclerosis, and memory: recent neuropsychological findings.

Authors:  B D Bell; K G Davies
Journal:  Neuropsychol Rev       Date:  1998-03       Impact factor: 7.444

Review 4.  Epilepsy surgery: chance for a cure.

Authors:  L Uber-Zak; D Blum
Journal:  Curr Neurol Neurosci Rep       Date:  2001-07       Impact factor: 5.081

5.  Long term follow-up of the first 70 operated adults in the Goteborg Epilepsy Surgery Series with respect to seizures, psychosocial outcome and use of antiepileptic drugs.

Authors:  Fredrik Asztely; Gerd Ekstedt; Bertil Rydenhag; Kristina Malmgren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-19       Impact factor: 10.154

Review 6.  The current treatment of epilepsy: a challenge of choices.

Authors:  Joseph I Sirven
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

7.  Prospective and longitudinal long-term employment outcomes after resective epilepsy surgery.

Authors:  Anna Edelvik; Roland Flink; Kristina Malmgren
Journal:  Neurology       Date:  2015-09-25       Impact factor: 9.910

8.  Identifying the trajectory of social milestones 15-20 years after epilepsy surgery: Realistic timelines for postsurgical expectations.

Authors:  Honor Coleman; Anne McIntosh; Sarah J Wilson
Journal:  Epilepsia Open       Date:  2019-06-13

9.  Determining surgical candidacy in temporal lobe epilepsy.

Authors:  Alireza Mansouri; Aria Fallah; Taufik A Valiante
Journal:  Epilepsy Res Treat       Date:  2012-02-21

10.  The long-term outcomes of epilepsy surgery.

Authors:  Midhun Mohan; Simon Keller; Andrew Nicolson; Shubhabrata Biswas; David Smith; Jibril Osman Farah; Paul Eldridge; Udo Wieshmann
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.